Streetbeat News

DMTTF

Small Pharma Inc

Industry

Medicinal and Botanical Manufacturing

Open

0.11

Mkt cap

38M

Volume

109K

High

0.13

P/E Ratio

-2.23

52-wk high

0.19

Low

0.11

Div yield

N/A

52-wk low

0.04

MAPS Public Benefit Corporation, a subsidiary of MAPS, has raised over $100 million in Series A funding to support FDA approval of MDMA for PTSD treatment. The company will rebrand as Lykos Therapeutics. The investment reflects growing interest in psychedelic treatments for mental illnesses. Atai Life Sciences, Compass Pathways, and Cybin Inc. are also advancing in the psychedelic space with significant investments and acquisitions.

Portfolio Pulse from Maureen Meehan

January 06, 2024 | 8:59 pm

Psychedelics companies Cybin Inc. and Small Pharma Inc. have completed their acquisition agreement, making Small Pharma a wholly-owned subsidiary of Cybin. The combined company has received two patent grants from the USPTO and one from the European Patent Office. The AdvisorShares Psychedelics ETF has been showing a descending trend in its opening and closing prices. Other psychedelics stocks such as GH Research, COMPASS Pathways, Mind Medicine, Enveric Biosciences, Bright Minds Biosciences, Silo Pharma, Atai Life Sciences, Incannex Healthcare, FSD Pharma, and Cybin Inc. have also seen changes in their closing prices.

Portfolio Pulse from Lara Goldstein

October 30, 2023 | 2:48 am

Cybin (NYSE:CYBN) has received three new international patents for its deuterated psychedelics programs, two from the United States Patent and Trademark Office and one from the European Patent Office. The patents protect the composition of matter for certain deuterated DMT analogs and their medical use. The company's development programs are now protected by 33 granted patents and over 170 pending applications. Cybin is currently conducting Phase 1 clinical trials for its deuterated DMT compounds CYB004 and SPL028, and a Phase 2 clinical trial for its deuterated psilocybin analog CYB003.

Portfolio Pulse from Lara Goldstein

October 26, 2023 | 9:21 pm

Psychedelics companies Cybin Inc. (NYSE:CYBN) and Small Pharma Inc. (OTCQB:DMTTF) have completed their acquisition agreement, making Small Pharma a wholly-owned subsidiary of Cybin. The deal is seen as a significant milestone for Cybin, positioning it as a leader in the psychedelics sector. The combined company now has the industry’s largest deuterated DMT pipeline program and a large IP portfolio in the psychedelic drug development space. The merger is expected to accelerate innovation in the industry and deliver enhanced value for shareholders.

Portfolio Pulse from Lara Goldstein

October 23, 2023 | 5:39 pm

The article discusses the growing acceptance of psychedelic substances in treating mental health issues, with celebrities like Jada Pinkett Smith sharing their positive experiences. It also mentions the death of esteemed psychedelic researcher Dr. Roland Griffiths. A Congressional hearing on the use of psychedelics for mental health disorders was postponed. Harvard University is creating a Study of Psychedelics in Society and Culture, backed by a $16 million donation from a former Tesla employee. The article also provides updates on various companies in the psychedelic sector, including Small Pharma, Johnson & Johnson, Lucy Scientific, and others. The AdvisorShares Psychedelics ETF (PSIL) continues a descending trend.

Portfolio Pulse from Lara Goldstein

October 22, 2023 | 7:18 pm

Small Pharma Inc. (OTCQB:DMTTF) has released its Q2 2024 financial results ahead of its merger with Cybin Inc. (NYSE:CYBN). The results show a 58.6% six-month burn rate, with cash decreasing from $13.5 million in February 2023 to $5.6 million by August 2023. The company also reported a net loss of $2.98 million and $7.1 million for the three and six months ended August 31, 2023. The merger with Cybin is set to create a global DMT business.

Portfolio Pulse from Lara Goldstein

October 20, 2023 | 6:49 pm

Small Pharma Inc. (OTCQB:DMTTF) has received final approval from the Supreme Court of British Columbia for its acquisition by Cybin Inc. (NYSE:CYBN) in an all-share transaction. The deal is expected to close on or about October 23, 2023. After the completion, Small Pharma's shares will be delisted from the TSXV and OTCQB Venture Market.

Portfolio Pulse from Lara Goldstein

October 18, 2023 | 6:33 pm

Cybin Inc. (NYSE:CYBN) and Small Pharma Inc. (OTC:DMTTF) shareholders have approved the acquisition of the latter by the former. The FDA has issued a warning about the misuse of ketamine and ketamine-based drugs. The DEA has extended telemedicine flexibilities for controlled medications until the end of 2024. California Governor Gavin Newsom has vetoed a bill to decriminalize certain hallucinogens. Congress is discussing kratom product regulation. The AdvisorShares Psychedelics ETF (NYSE:PSIL) continues to show a downtrend in its opening price. Several psychedelic stocks, including GH Research (NASDAQ:GHRS), COMPASS Pathways (NASDAQ:CMPS), and Mind Medicine (NASDAQ:MNMD), also closed lower.

Portfolio Pulse from Lara Goldstein

October 16, 2023 | 7:57 pm

Cybin Inc. (NYSE:CYBN) and Small Pharma Inc. (OTCQB:DMTTF) have announced that their shareholders have approved the acquisition of Small Pharma by Cybin. The arrangement is subject to approval by BC’s Supreme Court and other customary closing conditions, with an expected effective date on or around October 23, 2023. Post-acquisition, Small Pharma will cease trading at TSXV and the OTCQB venture market.

Portfolio Pulse from Lara Goldstein

October 13, 2023 | 5:52 pm

The article discusses recent developments in the field of psychedelic therapies for mental health disorders. Small Pharma's (OTC:DMTTF) Phase 1b study on DMT and SSRIs for major depressive disorder (MDD) has released new findings. TheraPsil, a Canadian non-profit, has launched an MDMA-assisted psychotherapy training program. Apex Labs' psilocybin macrodose drug protocol has been approved for a Canadian veteran's treatment-resistant depression. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has been on a slow downtrend. Other companies mentioned include GH Research (NASDAQ:GHRS), COMPASS Pathways (NASDAQ:CMPS), Mind Medicine (NASDAQ:MNMD), Enveric Biosciences (NASDAQ:ENVB), Bright Minds Biosciences (NASDAQ:DRUG), Silo Pharma (NASDAQ:SILO), Atai Life Sciences (NASDAQ:ATAI), FSD Pharma (NASDAQ:HUGE), Incannex Healthcare (NASDAQ:IXHL), Lucy Scientific Discovery (NASDAQ:LSDI), and Cybin Inc. (NYSE:CYBN).

Portfolio Pulse from Lara Goldstein

October 02, 2023 | 1:46 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.